C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif chemokine receptor 7(CXCR7) regulates epithelial-mesenchymal transition process and promotes the metastasis of esophageal cancer by activating signal transducer and activator of transcription 3 (STAT3) pathway

References

• Uhlenhopp DJ, Then EO, Sunkara T, and Gaduputi, V, et al. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clinical Journal of Gastroenterology. 2020; 13(6):1010–21.
   PubMed Web of Science ®Google Scholar
• Then EO, Michell Lopez SS, Gayam V, et al. Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J Oncol. 2020;11(2):55.
   PubMedGoogle Scholar
• Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020;50(1):12–20.
   PubMed Web of Science ®Google Scholar
• Yang Y-M, Hong P, Xu WW, et al. Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 2020;5(1):1–11.
   PubMed Web of Science ®Google Scholar
• Cao -Y-Y, Yu J, Liu -T-T, et al. Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling. Cell Death Dis. 2018;9(2):1–13.
   PubMed Web of Science ®Google Scholar
• Tachimori Y. Pattern of lymph node metastases of squamous cell esophageal cancer based on the anatomical lymphatic drainage system: efficacy of lymph node dissection according to tumor location. J Thorac Dis. 2017;9(Suppl 8):S724.
   PubMed Web of Science ®Google Scholar
• Pearson GW. Control of invasion by epithelial-to-mesenchymal transition programs during metastasis. J Clin Med. 2019;8(5):646.
   PubMed Web of Science ®Google Scholar
• Loh C-Y, Chai JY, Tang TF, et al. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):1118.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018;12(4):361–373.
   PubMed Web of Science ®Google Scholar
• Hua W, Ten Dijke P, Kostidis S, et al. TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. Cell Mol Life Sci. 2020;77(11):2103–2123.
   PubMed Web of Science ®Google Scholar
• Marcuzzi E, Angioni R, Molon B, et al. Chemokines and chemokine receptors: orchestrating tumor metastasization. Int J Mol Sci. 2019;20(1):96.
   Web of Science ®Google Scholar
• Janssens R, Struyf S, Proost P. The unique structural and functional features of CXCL12. Cell Mol Immunol. 2018;15(4):299–311.
   PubMed Web of Science ®Google Scholar
• Mao TL, Fan KF, Liu CL. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer. Gene Ther. 2017;24(10):621–629.
   PubMed Web of Science ®Google Scholar
• Sánchez-Martín L, Sánchez-Mateos P, Cabañas C. CXCR7 impact on CXCL12 biology and disease. Trends Mol Med. 2013;19(1):12–22.
   PubMed Web of Science ®Google Scholar
• Huynh C, Dingemanse J, Zu Schwabedissen HEM, et al. Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions. Pharmacol Res. 2020;105092. DOI:10.1016/j.phrs.2020.105092
   PubMed Web of Science ®Google Scholar
• Daniel SK, Seo YD, and Pillarisetty VG. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies. Seminars in Cancer Biology; 2020 ;65:176-88.
   Google Scholar
• Nazari A, Khorramdelazad H, Hassanshahi G. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer. Int J Clin Oncol. 2017;22(6):991–1000.
   PubMed Web of Science ®Google Scholar
• Shi Y, Riese DJ, Shen J. The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer. Front Pharmacol. 2020;11:1969.
   Web of Science ®Google Scholar
• Guan W, Li F, Zhao Z, et al. Tumor-associated macrophage promotes the survival of cancer cells upon docetaxel chemotherapy via the CSF1/CSF1R–CXCL12/CXCR4 axis in castration-resistant prostate cancer. Genes (Basel). 2021;12(5):773.
   PubMed Web of Science ®Google Scholar
• Xu L, Li C, Hua F, et al. The CXCL12/CXCR7 signalling axis promotes proliferation and metastasis in cervical cancer. Med Oncol. 2021;38(5):1–10.
   Web of Science ®Google Scholar
• Qin Y, Wang F, Ni H, et al. Cancer-associated fibroblasts in gastric cancer affect malignant progression via the CXCL12-CXCR4 axis. J Cancer. 2021;12(10):3011.
   PubMed Web of Science ®Google Scholar
• Zhang M, Qiu L, Zhang Y, et al. CXCL12 enhances angiogenesis through CXCR7 activation in human umbilical vein endothelial cells. Sci Rep. 2017;7(1):1–9.
   PubMed Web of Science ®Google Scholar
• Liang K, Liu Y, Eer D, et al. High CXC chemokine ligand 16 (CXCL16) expression promotes proliferation and metastasis of lung cancer via regulating the NF-κB pathway. Med Sci Monit. 2018;24:405.
   PubMed Web of Science ®Google Scholar
• Song Z-Y, Wang F, Cui S-X, et al. Knockdown of CXCR4 inhibits CXCL12-induced angiogenesis in HUVECs through downregulation of the MAPK/ERK and PI3K/AKT and the Wnt/β-catenin pathways. Cancer Invest. 2018;36(1):10–18.
   PubMed Web of Science ®Google Scholar
• Wu S-G, Zhang -W-W, Sun J-Y, et al. Patterns of distant metastasis between histological types in esophageal cancer. Front Oncol. 2018;8:302.
   PubMed Web of Science ®Google Scholar
• Fares J, Fares MY, Khachfe HH, et al. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):1–17.
   PubMed Web of Science ®Google Scholar
• Li H, Wang Y, Lu Y, et al. Annexin A2 interacting with ELMO1 regulates HCC chemotaxis and metastasis. Life Sci. 2019;222:168–174.
   PubMed Web of Science ®Google Scholar
• Kalpana G, Figy C, Yeung M, et al. Reduced RhoA expression enhances breast cancer metastasis with a concomitant increase in CCR5 and CXCR4 chemokines signaling. Sci Rep. 2019;9(1):16351.
   PubMed Web of Science ®Google Scholar
• Qi S, Perrino S, Miao X, et al. The chemokine CCL7 regulates invadopodia maturation and MMP-9 mediated collagen degradation in liver-metastatic carcinoma cells. Cancer Lett. 2020;483:98–113.
   PubMed Web of Science ®Google Scholar
• Wang C, Chen W, Shen J. CXCR7 targeting and its major disease relevance. Front Pharmacol. 2018;9:641.
   PubMed Web of Science ®Google Scholar
• Qian T, Liu Y, Dong Y, et al. CXCR7 regulates breast tumor metastasis and angiogenesis in vivo and in vitro. Mol Med Rep. 2018;17(3):3633–3639.
   PubMed Web of Science ®Google Scholar
• Wu YC, Tang S-J, Sun GH, et al. CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer. Oncogene. 2016;35(16):2123–2132.
   PubMed Web of Science ®Google Scholar
• Décaillot FM, Kazmi MA, Lin Y, et al. CXCR7/CXCR4 heterodimer constitutively recruits β-arrestin to enhance cell migration. J Biol Chem. 2011;286(37):32188–32197.
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhang M, Li Y, et al. CXCR7 mediates neural progenitor cells migration to CXCL12 independent of CXCR4. Stem Cells. 2015;33(8):2574–2585.
   PubMed Web of Science ®Google Scholar
• Xu L, Li C, Hua F, et al. The CXCL12/CXCR7 signalling axis promotes proliferation and metastasis in cervical cancer. Med Oncol. 2021;38(5):58.
   PubMed Web of Science ®Google Scholar
• Xin Q, Zhang N, Yu H-B, et al. CXCR7/CXCL12 axis is involved in lymph node and liver metastasis of gastric carcinoma. World J Gastroenterol. 2017;23(17):3053–3065.
   PubMed Web of Science ®Google Scholar
• Li X, Wang X, Li Z, et al. Chemokine receptor 7 targets the vascular endothelial growth factor via the AKT/ERK pathway to regulate angiogenesis in colon cancer. Cancer Med. 2019;8(11):5327–5340.
   PubMed Web of Science ®Google Scholar
• Yang X-Y, Sheng Y. miR-101 represses T-cell acute lymphoblastic leukemia by targeting CXCR7/STAT3 axis. Oncol Res. 2019;27(9):997–1006.
   PubMed Web of Science ®Google Scholar
• Wu Y, Tian L, Xu Y, et al. CXCR7 silencing inhibits the migration and invasion of human tumor endothelial cells derived from hepatocellular carcinoma by suppressing STAT3. Mol Med Rep. 2018;18(2):1644–1650.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim J-E, Kim N, et al. Decursin inhibits tumor growth, migration, and invasion in gastric cancer by down-regulating CXCR7 expression. Am J Cancer Res. 2019;9(9):2007–2018.
   PubMed Web of Science ®Google Scholar